IQV logo

IQVIA Holdings Inc. Stock Price

NYSE:IQV Community·US$38.9b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 31 Fair Values set on narratives written by author

IQV Share Price Performance

US$225.63
25.05 (12.49%)
US$168.00
Fair Value
US$225.63
25.05 (12.49%)
34.3% overvalued intrinsic discount
US$168.00
Fair Value
Price US$225.63
AnalystLowTarget US$168.00
AnalystHighTarget US$268.00
AnalystConsensusTarget US$247.50

IQV Community Narratives

AnalystLowTarget·
Fair Value US$168 34.3% overvalued intrinsic discount

Rising Regulatory Burdens And High Debt Will Limit Operations

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value US$254.64 11.4% undervalued intrinsic discount

NVIDIA Partnership And AI Deployment Will Fuel Healthcare Digitization

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AnalystConsensusTarget·
Fair Value US$247.5 8.8% undervalued intrinsic discount

Analyst Commentary Highlights Resilience and Upgraded Valuation Outlook for IQVIA Holdings

0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
US$168
34.3% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
4.96% p.a.
Profit Margin
8.58%
Future PE
18.67x
Price in 2028
US$210.93

Trending Discussion

Updated Narratives

IQV logo

IQV: Earnings Reacceleration Will Drive Outperformance Into 2026

Fair Value: US$247.5 8.8% undervalued intrinsic discount
16 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
IQV logo

Rising Regulatory Burdens And High Debt Will Limit Operations

Fair Value: US$168 34.3% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
IQV logo

NVIDIA Partnership And AI Deployment Will Fuel Healthcare Digitization

Fair Value: US$254.64 11.4% undervalued intrinsic discount
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Good value with limited growth.

1 Risk
2 Rewards

IQVIA Holdings Inc. Key Details

US$15.9b

Revenue

US$10.5b

Cost of Revenue

US$5.4b

Gross Profit

US$4.1b

Other Expenses

US$1.3b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
7.53
33.78%
8.07%
238.7%
View Full Analysis

About IQV

Founded
n/a
Employees
91000
CEO
Ari Bousbib
WebsiteView website
www.iqvia.com

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.

Recent IQV News & Updates

Recent updates

No updates